The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Developing guidelines for the management of infections following treatment with bispecifics
Muhammad Bilal Abid, MD, UT Houston McGovern School of Medicine, Houston, TX, discusses the risk of infections associated with the use of bispecific antibodies when treating hematological malignancies, including multiple myeloma and lymphoma. Dr Bilal Abid also shares insights into his work which aims to develop recommendations and guidelines for managing and treating infections in this setting. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
